Use of extracts from Pelargonium species

Details Use of extracts from Pelargonium species Use of extracts from Pelargonium species

2004-10-26

2009-11-03

Flood, Michele (Department: 1655)

Drug, bio-affecting and body treating compositions

Plant material or plant extract of undetermined constitution...

C514S783000

Reexamination Certificate

active

07611734

ABSTRACT:
The use of extracts fromPelargoniumspecies or plant parts thereof, particularly fromP. sidoidesandP. reniformefor the prophylaxis or treatment of disease-related behavioral changes, the chronic or post-viral asthenia syndrome and/or stress-induced chronic pathological conditions as well as pharmaceutical preparations containing these extracts are described.

REFERENCES:
patent: 2002/0187115 (2002-12-01), Pushpangadan et al.
patent: 2 355 189 (2001-04-01), None
patent: 2 381 195 (2003-04-01), None
patent: WO-96/05849 (1996-02-01), None
patent: WO-03/028746 (2003-04-01), None
patent: WO03028746 (2003-04-01), None
Kolodziej, Traditionally usedPelargoniumspecies: chemistry and biological activity of umckaloabo extracts and their constituents. Current Topics in Phytochemistry 3: 77-93, 2000.
Kayser et al., Antibacterial activity of extracts and constituents ofPelargonium sidoidesandPolargonium reniforme. Planta Medica 63: 508-510, 1997.
Greenway et al., Research: Relief of Post-Herpetic Neuralgia Pain with Topical Geranium Oil [Fibromyalgia & Pain related news]. Fibromyalgiasupport.com, Oct. 10, 2003.
Bourin et al, European Journal of Pharmacology 463: 55-65, 2003.
Hascoet et al, Prog. Neuro-Psychuat 25: 141-166, 2001.
Phillipson, Phytotherapy Research 13: 2-8, 1999.
Revilla et al, J. Agric. Food Chem 46: 4592-4597, 1998.
Haidvogl et al., Acute bronchitis in children, Zeitschrift fur Phytotherapie, (1996) vol. 17, No. 5, pp. 300-313.
Sampair et al., Immune activation byCorynebacterium parvumantigen induces alterations of circadian rhythm in C57B/6 mice, Society for Neuroscience Abstracts, (2001) vol. 27, No. 2, pp. 2236. print.
Kayser et al., Immunomodulatory principles ofPelargonium sidoides, Phytotherapy research : PTR, (Mar. 2001) vol. 15, No. 2, pp. 122-126.
Haidvogl et al. Zeitschrift fur Phytotherapie, 17(5):300-313 (1996); XP008011447.
Kolodziej et al., Zeitschrift fur Phytotherapie, 19(3):141-151 (1998); XP008011448.
Yirmiya, Current Opinion on Psychiatry, 10:470-476 (1997).
Dantzer, Brain, Behavior, and Immunity, 18:1-6 (2004).
Miller, Brain, Behavior, and Immunity, 17:S132-S134 (2003).
Reichenberg et al., Arch. Gen. Psychiatry, 58:445-452 (2001).
Kent et al., TiPS, 13:24-28 (1992).
Kozak et al., The American Physiological Society, pp. R1298-R1307 (1997).
Dantzer, Brain, Behavior, and Immunity, 15:7-24 (2001).
Kelley et al., Brain. Behavior, and Immunity 17:S112-S118 (2003).
Dantzer et al., Brain, Behavior, and Immunity, 17:S119-S124 (2003).
Pall, Medical Hypotheses (57(2):139-145 (2001).
Miller et al., Health Psychology, 21(6):531-541 (2002).
Kolodziej et al., Phytomedicine, 10(Suppl. IV):18-24 (2003).
H. Matthys et al., “Efficacy and safety of an extract ofPelargonium sidoides(EPs 7630) in adults with acute bronchitis—A randomised, double-blind, placebo-controlled trial”,Phytomedicine, vol. 10, Supplement 4, pp. 7-17 (2003).
M. Haidvogl et al., “Treatment effect and safety of EPs 7630-solution in acute bronchitis in childhood: Report of a multicentre observational study”,Phytomedicine, vol. 14, Supplement 6, pp. 60-64 (2007).
M. Bourin et al., “The mouse light/dark box test”,European Journal of Pharmacology, vol. 463, pp. 55-65 (2003).
P.W. Laidler et al., “The Magic Medicine of the Hottentots”,South African Journal of Science, vol. XXV, pp. 433-447 (1928).
M. Heger et al., “Non-streptococcal tonsillo-pharyngitis in children: Efficacy of an extract fromPelargonium sidoides(EPs 7630) compared to placebo”,Phytopharmaka VII, (2002).
H. Kolodziej et al., “Medicinal Use of South African Pelargoniums—Studies ofPerlargonium sidoidesandP. reniforme”, Deutsche Apotheker Zeitung,, 135(10), pp. 23-34 (1995).
I. Konig et al., “Respiratory Tract Therapy on a Natural Basis”,Therapie Woche, vol. 45, pp. 1123-1126 (1995).
A. Sechehaye et al., “The treatment of organic and surgical tuberculosis with Umckaloabo—Internal healing methods (Stevens cure)—Historical aspects, experimental research, clinical observations, results”,English translation of the last chapter of(VI: Conclusions), pp. 140-141 (1937).
B. Blochin et al., “Umckaloabo compared with acetylcysteine in children with acute bronchitis—A prospective, randomized, controlled opens tudy of efficacy and tolerability”,Translation from Der Kassenarzt, pp. 46-50 (1999).
M. Hascoet et al., “The mouse light-dark paradigm: A review”,Prog. Neuro-Phychopharmacol. &Biol. Phychiat, vol. 25, pp. 141-166 (2001).
Mnyamezeli Nxakala's Affidavit (2008).
Elizabeth Nkqayi's Affidavit (2008).
Zamile Ngethu's Affidavit (2008).
Yaziew Gidi's Affidavit (2008).
Notsomi Bevile's Affidavit (2008).
Notini Cylvia Khulungu's Affidavit (2008).
Red List 2002—Medicinal Product Register for Germany (including medicinal products approved in the EU and certain medical devices); Editor: Rote Liste® Service GmbH, Frankfurt/Main; ECV—Editio Cantor Verlag, Aulendorf.
Red List 2003—Medicinal Product Register for Germany (including medicinal products approved in the EU and certain medical devices); Editor: Rote Liste® Service GmbH, Frankfurt/Main; Editio Cantor Verlag, Aulendorf.
Information for Patent/Patent Application: “Umckaloabo® Solution”; Approval No. 57602 (Swissmedic); Approval Holder: Schwabe Pharma AG, Kussnacht am Rigi.
Internet address: www.gesundheit.de, “Common Cold, Influenza, Influenza Infection” (2005).
Internet address: www.medizininfo.de/immunsystem/erkaelt/erkaeltung.htm, “Immune System”, (2008).
H. Lewitzka-Reitner et al., “Grosses Gesundheits-Lexikon—An Encyclopedia concerning health related topics” (1987).
“Rigorous limitation for indication of UMCKALOABO”,Arznel-telegramm 2006, 37(10), pp. 92-93 (2006).
“Benefit ofPelargoniumextract (UMCKALOABO) in accute bronchitis documented”,Arznei-Telegramm, 39(10), pp. 104-106 (2008).
M. Viljoen et al., “Non-termination of sickness behavior as precipitating factor for mental disorders”,Medical Hypotheses, vol. 65, pp. 316-329 (2005).
M.L. Pall et al., “Common epiology of posttraumatic stress disorder, fibromyalgia, chronic fatigue syndrome and multiple chemical sensitivity via elevated nitric oxide/peroxynitrite”,Medical Hypotheses, 57(2), pp. 139-145 (2001).
R. Yirmiya et al., “Behavioral and psychological effects of immune activation: implications for ‘depression due to a general medical condition’”,Current Opinion in Psychiatry, vol. 10, pp. 470-476 (1997).
S. Kent et al., “Sickness behavior as a new target for drug development”,TiPS, vol. 13, pp. 24-28 (1992).

Affiliated with

Also associated with

Rating

Use of extracts from Pelargonium species does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of extracts from Pelargonium species, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of extracts from Pelargonium species will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4072180